Literature DB >> 825035

Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats.

R E Scott, H G Robson.   

Abstract

Rats made neutropenic with cyclophosphamide were infected intraperitoneally with Pseudomonas aeruginosa. The challenge organism was killed synergistically in vitro by the combination of gentamicin and carbenicillin. Untreated neutropenic rats infected with 3 x 10(6)Pseudomonas died between days 2 and 7, and the overall mortality was 70%. Groups of infected neutropenic rats were treated intramuscularly with 1.5 or 6 mg of gentamicin per kg per dose, 100 or 400 mg of carbenicillin per kg per dose, or 1.5 mg of gentamicin and 100 mg of carbenicillin per kg per dose. Treatment was begun at 2 h postinfection and was continued every 8 h for about 72 h. Cultures of blood and peritoneal washings were performed in control and treated rats at 1, 4, 24, 48, and 72 h postinfection. Gentamicin at either dose level was ineffective in preventing death, but mortality was significantly reduced by high-dose carbenicillin and low-dose combination therapy. In addition, the latter regimens sterilized the peritoneal fluid and blood. Carbenicillin and gentamicin showed in vivo synergy in the treatment of neutropenic Pseudomonas-infected rats.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 825035      PMCID: PMC429808          DOI: 10.1128/AAC.10.4.646

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Advances in the management of Pseudomonas aeruginosa infections in cancer patients.

Authors:  G P Bodey; V Rodriguez
Journal:  Eur J Cancer       Date:  1973-06       Impact factor: 9.162

2.  Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer.

Authors:  S C Schimpff; W H Greene; V M Young; P H Wiernik
Journal:  Eur J Cancer       Date:  1973-06       Impact factor: 9.162

3.  Carbenicillin therapy for pseudomonas infections.

Authors:  G P Bodey; J P Whitecar; E Middleman; V Rodriguez
Journal:  JAMA       Date:  1971-10-04       Impact factor: 56.272

4.  Carbenicillin therapy of gram-negative bacilli infections.

Authors:  G P Bodey; V Rodriguez; J K Luce
Journal:  Am J Med Sci       Date:  1969-06       Impact factor: 2.378

5.  Feasibility of administering aminoglycoside antibiotics by continuous intravenous infusion.

Authors:  G P Bodey; H Y Chang; V Rodriguez; D Stewart
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

6.  Gentamicin: clinical use with carbenicillin and in-vitro studies with recent isolates of Pseudomonas aeruginosa.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

7.  Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin.

Authors:  G G Jackson; L J Riff
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

8.  Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever.

Authors:  J E Pennington; D C Dale; H Y Reynolds; J D MacLowry
Journal:  J Infect Dis       Date:  1975-09       Impact factor: 5.226

9.  Therapy of neutropenic rats infected with Pseudomonas aeruginosa.

Authors:  R M Lumish; C W Norden
Journal:  J Infect Dis       Date:  1976-05       Impact factor: 5.226

10.  Determinants of infection in the peritoneal cavity. I. Response to and fate of Staphylococcus aureus and Staphylococcus albus in the mouse.

Authors:  Z A COHN
Journal:  Yale J Biol Med       Date:  1962-08
View more
  20 in total

Review 1.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 2.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Authors:  Rajbharan Yadav; Kate E Rogers; Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

4.  Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.

Authors:  L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

5.  Antibacterial efficacy of cefazolin and cephradine in neutropenic mice.

Authors:  M W Kunst; H Mattie; R van Furth
Journal:  Infection       Date:  1979       Impact factor: 3.553

6.  Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats.

Authors:  D E Johnson; B Thompson; F M Calia
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

7.  Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.

Authors:  L Mintz; W L Drew
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

8.  In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus.

Authors:  S H Zinner; J Klastersky; H Gaya; C Bernard; J C Ryff
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

9.  Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens.

Authors:  T O Kurtz; D J Winston; D A Bruckner; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

10.  Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.

Authors:  N X Chin; K Jules; H C Neu
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.